ATE219374T1 - Medikamente für die behandlung oder vorbeugung von thrombocytopenie - Google Patents

Medikamente für die behandlung oder vorbeugung von thrombocytopenie

Info

Publication number
ATE219374T1
ATE219374T1 AT97901818T AT97901818T ATE219374T1 AT E219374 T1 ATE219374 T1 AT E219374T1 AT 97901818 T AT97901818 T AT 97901818T AT 97901818 T AT97901818 T AT 97901818T AT E219374 T1 ATE219374 T1 AT E219374T1
Authority
AT
Austria
Prior art keywords
thrombocytopenia
medications
prevention
treatment
pth
Prior art date
Application number
AT97901818T
Other languages
English (en)
Inventor
Masahiko Tamura
Yasuhiro Oda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE219374T1 publication Critical patent/ATE219374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Seal Device For Vehicle (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT97901818T 1996-02-01 1997-02-03 Medikamente für die behandlung oder vorbeugung von thrombocytopenie ATE219374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1670196 1996-02-01
PCT/JP1997/000255 WO1997027870A1 (en) 1996-02-01 1997-02-03 Preventives and remedies for thrombocytopenia

Publications (1)

Publication Number Publication Date
ATE219374T1 true ATE219374T1 (de) 2002-07-15

Family

ID=11923601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901818T ATE219374T1 (de) 1996-02-01 1997-02-03 Medikamente für die behandlung oder vorbeugung von thrombocytopenie

Country Status (6)

Country Link
US (3) US6342477B1 (de)
EP (2) EP0878201B1 (de)
AT (1) ATE219374T1 (de)
AU (1) AU1558197A (de)
DE (1) DE69713485T2 (de)
WO (1) WO1997027870A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
TR199902800T2 (xx) 1997-05-15 2000-04-21 Chugai Seiyaku Kabushiki Kaisha Ka�eksiyi tedavi edici madde.
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
WO2001002011A1 (fr) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
EP1221966B1 (de) * 1999-09-20 2005-11-16 Eli Lilly And Company Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
ATE420661T1 (de) 2000-04-28 2009-01-15 Chugai Pharmaceutical Co Ltd Zellproliferation-inhibitoren
US7635477B2 (en) * 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
WO2004011484A2 (en) * 2002-07-25 2004-02-05 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
US7425553B2 (en) * 2003-05-30 2008-09-16 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja) * 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
EP1817056B1 (de) * 2004-11-11 2014-08-13 The General Hospital Corporation Parathyroidhormonrezeptoraktivierung sowie stamm- und vorläuferzellenausdehnung
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1961765A1 (de) * 2006-12-08 2008-08-27 Zealand Pharma A/S Verkürzte PTH-Peptide mit zyklischer Konformation
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
WO2010039872A1 (en) * 2008-10-01 2010-04-08 The Board Of Trustees Of The University Of Illinois Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPH05509098A (ja) 1990-07-13 1993-12-16 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ３，６または９位において変性されている副甲状腺ホルモン類似体
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use

Also Published As

Publication number Publication date
US20050197296A1 (en) 2005-09-08
EP0878201A4 (de) 1999-11-10
WO1997027870A1 (en) 1997-08-07
DE69713485D1 (de) 2002-07-25
US7268110B2 (en) 2007-09-11
EP0878201B1 (de) 2002-06-19
EP0878201A1 (de) 1998-11-18
US6342477B1 (en) 2002-01-29
US20020058626A1 (en) 2002-05-16
EP1166796A3 (de) 2002-03-06
DE69713485T2 (de) 2003-01-30
US6956022B2 (en) 2005-10-18
EP1166796A2 (de) 2002-01-02
AU1558197A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
DE69713485D1 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
ATE213390T1 (de) Wirkstoff zur erhöhung der produktion und der zucht von tieren in der geflügelindustrie
ES2147740T3 (es) Metodo para el tratamiento de enfermedades vasculares hiperproliferativas utilizando rapamicina, eventualmente en combinacion con acido micofenolico.
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE3579151D1 (de) Vorrichtung zur behandlung der oberschenkelknochenbrueche.
DE69101080D1 (de) Diätfaser, Verfahren und physiologische aktive Zusammensetzung, die diese als aktives Ingredient enhält.
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
DE69000510D1 (de) Zusammensetzung fuer die behandlung von wasser oder waesserigen systemen.
DE3876140D1 (de) Zusammensetzung fuer die behandlung von textilien.
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
DE3877521D1 (de) Vorrichtung fuer die behandlung von abwasser aus photoprozessen.
ATE120612T1 (de) Unterdrückung des mercaptangeruches von organothiophosphatbioziden.
DE69227745D1 (de) Pharmazeutische Zusammensetzungen zur topischen Anwendung die ein Chelatierungsmittel, ein Tocopherol und einen antimikrobiellen Wirkstoff enthalten
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ZA916295B (en) Processes and agents for combating fleas
DE3875881D1 (de) Vorrichtung fuer die behandlung von abwasser aus photoprozessen.
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
ATE200026T1 (de) Behandlung von laminitis
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
DE69827163D1 (de) Phytase zur vorbeugung oder behandlung von mastitis
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
DE69114922D1 (de) Polysulfidverbindungen und Lipidperoxidierungsinhibitore, die diese Polysulfidverbindungen als aktive Zutaten enthalten.